Endoscopic ablation of Barrett's oesophagus: A randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 11-12, 2004, Pages 1289-1296

  Kelty, C J ^a,b   Ackroyd, R ^b   Brown, N J ^a   Stephenson, T J ^b   Stoddard, C J ^b   Reed, M W R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ANALGESIC AGENT; ONDANSETRON;

ADULT; AGED; ARGON PLASMA COAGULATION; ARTICLE; BARRETT ESOPHAGUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPHAGIA; ENDOSCOPIC THERAPY; ERYTHEMA; ESOPHAGUS; ESOPHAGUS CARCINOMA; ESOPHAGUS PERFORATION; ESOPHAGUS STRICTURE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RED LIGHT; RISK FACTOR; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; BARRETT ESOPHAGUS; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LASER COAGULATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 11144260930     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02277.x     Document Type: Article

References (49)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
2. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26: 2-8.
3. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109: 1541-6.
4. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25: 982-93.
5. Sjogren RW Jr, Johnson LF. Barrett's esophagus: a review. Am J Med 1983; 74: 313-21.
6. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
7. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9.
8. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212-5.
9. Solaymani-Dodaran M, Logan RP, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 1070-4.
10. Burke AP, Sobin LH, Shekitka KM, Helwig EB. Dysplasia of the stomach and Barrett esophagus: a follow-up study. Mod Pathol 1991; 4: 336-41.
11. Low DE, Levine DS, Dail DH, Kozarek RA. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999; 94: 80-5.
12. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12: 893-7.
13. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
14. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-22.
15. Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett's esophagus by laser ablation in an anacid environment. Dig Dis Sci 1993; 38: 365-8.
16. Thomas P, Doddoli C, Lienne P, et al. Changing patterns and surgical results in adenocarcinoma of the oesophagus. Br J Surg 1997; 84: 119-25.
17. Salo JA, Salminen JT, Kiviluoto TA, et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann Surg 1998; 227: 40-4.
18. Gossner L, May A, Stolte M, Seitz G, Hahn EG, Ell C. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc 1999; 49: 8-12.
19. Barham CP, Jones RL, Biddlestone LR, Hardwick RH, Shepherd NA, Barr H. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut 1997; 41: 281-4.
20. Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA. The histopathology of treated Barrett's esophagus: squamous re-epithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998; 22: 239-45.
21. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996; 44: 532-5.
22. Sharma P, Bhattacharyya A, Garewal HS, Sampliner RE. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest Endosc 1999; 50: 159-64.
23. Endo M. Endoscopic resection as local treatment of mucosal cancer of the esophagus. Endoscopy 1993; 25: 672-4.
24. Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-5.
25. Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000; 95: 1661-8.
26. Mork H, Barth T, Kreipe HH, et al. Reconstitution of squamous epithelium in Barrett's oesophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998; 33: 1130-4.
27. Van Laethem JL, Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-51.
28. Ackroyd R, Tam W, Schoeman M, Devitt PG, Watson DI. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc 2004; 59: 1-7.
29. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999; 49: 1-7.
30. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000; 47: 612-7.
31. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114: 448-55.
32. Hage M, Siersema PD, van Dekken H, et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 2004; 53: 785-90.
33. Ackroyd R, Kelty CJ, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 2003; 35: 496-501.
34. Morris CD, Byrne JP, Armstrong GR, Attwood SE. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001; 88: 1357-62.
35. Kelty CJ, Ackroyd R, Brown NJ, Brown SB, Reed MW. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc 2004; 18: 452-8.
36. Ackroyd R, Brown N, Vernon D, et al. 5-Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: a pharmacokinetic study. Photochem Photobiol 1999; 70: 656-62.
37. Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res 1997; 68: 31-7.
38. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584-5.
39. Zoepf T, Alsenbesy M, Jakobs R, Apel D, Rosenbaum A, Riemann JF. Photodynamic therapy (PDT) versus argon plasma coagulation (APC) for ablative therapy of Barrett's esophagus. Gastrointest Endosc 2003; 57: AB139.
40. van den Boogert J, van Staveren HJ, de Bruin RW, Eikelaar JH, Siersema PD, van Hillegersberg R. Photodynamic therapy for esophageal lesions: selectivity depends on wavelength, power, and light dose. Ann Thorac Surg 1999; 68: 1763-9.
41. Langmack K, Mehta R, Twyman P, Norris P. Topical photodynamic therapy at low fluence rates-theory and practice. J Photochem Photobiol B 2001; 60: 37-43.
42. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol 1998; 93: 332-5.
43. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000; 46: 574-7.
44. Bonavina L, Ceriani C, Carazzone A, Segalin A, Ferrero S, Peracchia A. Endoscopic laser ablation of nondysplastic Barrett's epithelium: is it worthwhile? J Gastrointest Surg 1999; 3: 194-9.
45. Kelty C, Ackroyd R. Re-epithelialisation of Barrett's oesophagus. Gut 2000; 47: 741.
46. Eisen GM. Ablation therapy for Barrett's esophagus. Gastrointest Endosc 2003; 58: 760-9.
47. Sharma P, Reker D, Falk GW, Johnston M, Weston AP, Sampliner R. Progression of Barrett's esophagus to high grade dysplasia and cancer: preliminary results of the BEST (Barrett's Esophagus Study) Trial. Gastroenterology 2001; 120: A16.
48. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000; 119: 624-30.
49. Wang KK, Wong Kee Song L, Buttar NS, Papenfuss S, Lutzke LS. Barret's esophagus after photodynamic therapy: risk of cancer development during long-term follow up. Gastroenterology 2004; 126: A50.